Fabien Zoulim

Head, Viral Hepatitis Team at Centre Léon Bérard Lyon et Rhône-Alpes

Fabien Zoulim

Fabien Zoulim

Head, Viral Hepatitis Team at Centre Léon Bérard Lyon et Rhône-Alpes

Overview
RelSci Relationships

122

Number of Boards

4

Relationships
View Relationship Details
RelSci Relationships are individuals Fabien Zoulim likely has professional access to. A relationship does not necessarily indicate a personal connection.
Jean-Yves Blay

General Director at Centre Léon Bérard Lyon et Rhône-Alpes

Relationship likelihood: Strong

Philippe Archinard

Chief Executive Officer at Transgene SA

Relationship likelihood: Strong

Osvaldo Flores

Co-Founder at Novira Therapeutics, Inc.

Relationship likelihood: Strong

Christophe Ancel

Vice President-Responsible Pharmacist, Quality & Deputy Chief Executive Officer, Member of the Management Committee at Transgene SA

Relationship likelihood: Strong

Eric Quéméneur

Deputy Chief Executive Officer, Director-Research & Development at Transgene SA

Relationship likelihood: Strong

Roger Pomerantz

President & Chief Executive Officer at ContraFect Corp.

Relationship likelihood: Strong

Philippe Gallay

Scientific Advisor at NeuroVive Pharmaceutical AB

Relationship likelihood: Strong

Heiner Wedemeyer

Member, Scientific Advisory Board at Novira Therapeutics, Inc.

Relationship likelihood: Strong

Richard Wilber

Member, Scientific Advisory Board at Novira Therapeutics, Inc.

Relationship likelihood: Strong

Jordan Feld

Professional at McLaughlin-Rotman Centre for Global Health

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
Business Wire
October 17, 2019
ENYO Pharma Announces Multiple EYP001 Data Presentations At AASLD Conference; ? Four Poster Presentations and One Oral presentation For Lead Compound EYP001 ? ? ENYO to Hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists
Business Wire
November 12, 2018
Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
Business Wire
October 10, 2018
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
Business Wire
October 23, 2017
TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B
GlobeNewswire
April 20, 2017
Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex (TXL„¢) Antiviral Activity in Hepatitis B (HBV) Patients
Trending People
Richard Michael DeWine
Guest lineups for the Sunday news shows - Associated Press
Oprah Winfrey
Oprah shows the world how it's done - CNN
Jennifer Rene Psaki
US to open more beds for immigrant children as numbers rise - Associated Press
LeBron James
Who is playing in the NBA All-Star game and what are the teams? - The Independent UK
Jerome H. Powell
TREASURIES-Yields retreat after 10-year hits near 13-month high - Nasdaq
Trending People
Richard Michael DeWine
Guest lineups for the Sunday news shows - Associated Press
Oprah Winfrey
Oprah shows the world how it's done - CNN
Jennifer Rene Psaki
US to open more beds for immigrant children as numbers rise - Associated Press
LeBron James
Who is playing in the NBA All-Star game and what are the teams? - The Independent UK
Jerome H. Powell
TREASURIES-Yields retreat after 10-year hits near 13-month high - Nasdaq
Paths to Fabien Zoulim
Potential Connections via
Relationship Science
You
Fabien Zoulim
Head, Viral Hepatitis Team at Centre Léon Bérard Lyon et Rhône-Alpes
Career History
Professor, Medicine
Current
University of Lyon

The University of Lyon, located in Lyon and Saint-Étienne, France, is a center for higher education and research comprising 16 institutions of higher education. The three main universities in this center are: Claude Bernard University Lyon 1, which focuses upon health and science studies and has approximately 27,000 students; Lumière University Lyon 2, which focuses upon the social sciences and has about 30,000 students; Jean Moulin University Lyon 3, which focuses upon the law and humanities with about 20,000 students.[

Head, Hepatology Department
Current
Hospices Civils de Lyon

Hospices Civils de Lyon is a company headquartered in Lyon, France and ultimately controlled by the Government of France, that provides health care services.

Head, Viral Hepatitis Team
Current
Centre Léon Bérard Lyon et Rhône-Alpes

Boards & Committees
Member, Scientific Advisory Board
2016 - Current
Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Member, Scientific Advisory Board
Current
Arbutus Biopharma Corp.

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Member, Scientific Advisory Board
Current
Novira Therapeutics, Inc.

Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA.
Other Affiliations

Fabien Zoulim is affiliated with University of Lyon, Hospices Civils de Lyon, Centre Léon Bérard Lyon et Rhône-Alpes, Hepion Pharmaceuticals, Inc., Arbutus Biopharma Corp., Novira Therapeutics, Inc., Transgene SA

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fabien Zoulim. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fabien Zoulim's profile does not indicate a business or promotional relationship of any kind between RelSci and Fabien Zoulim.